Budget initiatives announced in September to address structural deficits are starting to make a difference. Shereef Elnahal, M.D., says, “What we’re doing more globally to improve financial performance is to grow in areas that matter to patients and their families, and make that growth garner more revenue over expenses.”

Coverage of entrepreneur Michael Dell and his wife, Susan Dell, becoming the first donors to contribute more than $1 billion to the University of Texas at Austin mentions other record-breaking donations, such as Phil and Penny Knight’s $2 billion pledge to OHSU.

Nathan McConkey, D.O., performed the first MAGiC procedure in the U.S. using robotically navigated magnetic interventional cardiac ablation catheter on a patient with complex congenital heart disease.

A news wire press release highlights that Nathan McConkey, D.O., performed the first MAGiC procedure in the U.S. using robotically navigated magnetic interventional cardiac ablation catheter on a patient with complex congenital heart disease.

Blavity’s coverage of TikTok influencer Pinkydoll’s heart attack mentions OHSU Knight Cardiovascular Institute research.

A story by KDRV-TV mentions that the OHSU Knight Cancer Institute will bring its giant inflatable colon to the Living Well Health Fair in Klamath Falls.

Katie Au, M.D., and Katherine Jorda, M.D., are featured in the Advancing Health podcast of the American Hospital Association exploring how trauma can emerge during pregnancy, labor or postpartum.

In the OHSU podcast Innovate Health, Tim Joslin, M.D., shares the early groundwork, evaluation and guiding principles behind AI scribe adoption, including privacy considerations and clinician control. Brian Ricci, M.D., talks about what it’s like using AI scribe in everyday practice: how it changes the feel of the visit, supports clear next steps for patients and helps reduce after-hours documentation.

National Geographic reports that a new drug called daraxonrasib, which targets the KRAS genetic mutation found in nearly 90% of pancreatic tumors, nearly doubled median survival in a phase 3 clinical trial, marking what researchers are calling a potentially historic breakthrough in one of the deadliest and hardest-to-treat cancers. Robert Eil, M.D., says, “The idea that the first effective cancer vaccine is going to be against pancreas cancer—strange believability.”

Coverage continues on an OHSU study that developed a first-of-its-kind method to predict cancer patient survival using advanced molecular data from individual cells. Tao Ren, Ph.D., says, “This is the first kind of single-cell survival analysis that directly links individual tumor cells to patient outcomes”